UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

The Lancet (British edition), 2016-09, Vol.388 (10051), p.1281-1290

2016

Volltextzugriff (PDF)

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

The Lancet (British edition), 2012-12, Vol.380 (9857), p.1909-1915

2012

Volltextzugriff (PDF)

Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients

Alimentary pharmacology & therapeutics, 2020-04, Vol.51 (7), p.719-727

2020

Volltextzugriff (PDF)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

BMC gastroenterology, 2022-12, Vol.22 (1), p.498-498, Article 498

2022

Volltextzugriff (PDF)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

BMC gastroenterology, 2023-02, Vol.23 (1), p.31-31, Article 31

2023

Volltextzugriff (PDF)

Preoperative Predictors of Neoplasia in Patients Undergoing Small Bowel Resection for Complicated Crohn's Disease: A Multicentre Case-Control Study

Cancers, 2023-03, Vol.15 (7), p.2004

2023

Volltextzugriff (PDF)

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

Inflammatory bowel diseases, 2016-06, Vol.22 (6), p.1362-1369

2016

Volltextzugriff (PDF)

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM)

Journal of clinical medicine, 2020-01, Vol.9 (1), p.41

2020

Volltextzugriff (PDF)

Reply

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2431-2432

2023

Volltextzugriff (PDF)

Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease

Clinical gastroenterology and hepatology, 2023, Vol.21 (9), p.2431-2432

2023

Volltextzugriff (PDF)

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

Infection prevention in practice, 2023-03, Vol.5 (1), p.100267-100267, Article 100267

2023

Volltextzugriff (PDF)

Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study

Clinical gastroenterology and hepatology, 2024-05, Vol.22 (5), p.1127-1129.e2

2024

Volltextzugriff (PDF)

Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study: To appear in: Clinical Gastroenterology and Hepatology

Clinical gastroenterology and hepatology, 2024, Vol.22 (5), p.1127-1129

2024

Volltextzugriff (PDF)

Self-reported Impact of the Early 2020 COVID-19 Crisis on the Healthcare Pathway During and After Lockdown in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Practical Survey

Journal of patient experience, 2022-01, Vol.9, p.23743735221143736-23743735221143736

2022

Volltextzugriff (PDF)

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2338-2346.e3

2023

Volltextzugriff (PDF)

Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis

European journal of gastroenterology & hepatology, 2023-10, Vol.35 (10), p.1230-1230

2023

Volltextzugriff (PDF)

Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics

Digestive and liver disease, 2023-08, Vol.55 (8), p.1158-1160

2023

Volltextzugriff (PDF)

Reply

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2431

2023

Volltextzugriff (PDF)

Reply

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2431-2432

2023

Volltextzugriff (PDF)

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2018-04, Vol.154 (5), p.1334-1342.e4

2018

Volltextzugriff (PDF)

Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent

Alimentary Pharmacology & Therapeutics (Suppl), 2023-03, Vol.57 (6), p.676-688

2023

Volltextzugriff (PDF)

Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2023-01, Vol.29 (1), p.167-171

2023

Volltextzugriff (PDF)

Sa1769 PERSISTENCE OF BOWEL URGENCY DESPITE CLINICAL REMISSION AFTER INDUCTION THERAPY IS ASSOCIATED WITH UNFAVORABLE LONG-TERM OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE MULTICENTER UC-RGENCY STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-515-S-515

2024

Volltextzugriff (PDF)

Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis

Clinical gastroenterology and hepatology, 2019-02, Vol.17 (3), p.494-501

2019

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(174)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

Preoperative Predictors of Neoplasia in Patients Undergoing Small Bowel Resection for Complicated Crohn's Disease: A Multicentre Case-Control Study

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM)

Reply

Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study

Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study: To appear in: Clinical Gastroenterology and Hepatology

Self-reported Impact of the Early 2020 COVID-19 Crisis on the Healthcare Pathway During and After Lockdown in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Practical Survey

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study

Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics

Reply

Reply

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent

Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases

Sa1769 PERSISTENCE OF BOWEL URGENCY DESPITE CLINICAL REMISSION AFTER INDUCTION THERAPY IS ASSOCIATED WITH UNFAVORABLE LONG-TERM OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE MULTICENTER UC-RGENCY STUDY

Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis

Suchergebnisse filtern